Biogen and Alkermes Announce FDA Approval of VUMERITY™ (diroximel fumarate) for Multiple Sclerosis – VUMERITY, a New Oral Treatment Option...
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies New...
Biogen and Samsung Bioepis to Present Data for Infliximab and Adalimumab Biosimilars at United European Gastroenterology Week Data highlights...
Landmark NURTURE Study of Infants with Spinal Muscular Atrophy (SMA) Treated Pre-Symptomatically with SPINRAZA® (nusinersen) Published in...
Biogen Announces Leadership Update Dr. Alfred Sandrock is named Executive Vice President, Research and Development and continues as Chief...
Interferon Beta Treatments, Including PLEGRIDY® (peginterferon beta-1a) and AVONEX® (interferon beta-1a), Receive Positive CHMP Opinion for Use...
Biogen Advances Spinal Muscular Atrophy (SMA) Clinical Research with New Study Evaluating a Higher Dose of SPINRAZA® (nusinersen) and...
Biogen Ranked #1 Biotechnology Company on Dow Jones Sustainability World Index CAMBRIDGE, Mass., Sept. 17, 2019 (GLOBE NEWSWIRE) -- Biogen...
New Research Demonstrate Biogen’s Continued Commitment to Improve Care of Patients with Multiple Sclerosis Across Treatment Spectrum Data...
New Data Presented at ECTRIMS Reinforce Long-term Benefits of TECFIDERA® (dimethyl fumarate) Over 10 Years TECFIDERA consistently maintained...
Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with...
Idera is Developing Targeted Immune Therapies Based on Toll-like Receptors CAMBRIDGE, Mass., Sept. 12 /PRNewswire-FirstCall/ -- Hybridon, Inc...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.